Bio-Rad Laboratories, Inc. Class A Common Stock vs KLA Corp. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while KLA Corp. trades at $203.79 (market cap $251.82B). The key difference: KLA Corp. is far larger — about 26.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and KLA Corp. pays a 0.48% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | KLAC | |
|---|---|---|
Market Cap | $9.39B | $251.82B |
Sector | Health | Technology |
52-Week High | $356.25 | $301.71 |
52-Week Low | $241.71 | $84.39 |
Enterprise Value | $9.14B | $253.07B |
Dividend Yield | — | 0.48% |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
KLA Corporation (KLAC) trades at $198.11, up 2.53% today, with a neutral technical signal despite bullish moving averages. The stock shows strong fundamentals, including a 35.57% net income margin and consistent earnings beats, with Q3 2026 EPS expected at $1.17. Recent corporate actions include a 1:10 stock split and a $2.30 dividend, while cash flow remains positive at $101.78M in 2025. Analyst sentiment is optimistic, with a $246.93 consensus price target implying significant upside.
The outlook for KLAC is positive, driven by AI-driven semiconductor demand and robust profitability, but risks include high valuation multiples and market volatility. Investment opportunities center on growth in advanced packaging, with Wall Street largely bullish; however, investors should monitor competitive pressures and economic cycles that could impact the chip equipment sector.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →